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neutron scattering techniques, of new liposomal aggregates obtained by co-assembling an amphiphilic molecule containing
a platinum complex, Peg1500-Lys(Pt-aminoEtGly)-Lys(C18)2, (abbreviated as (C18)2-PKAG-Pt), with a second amphiphilic mono-
mer, (C18H37)2NCO(CH2)2CO(AdOO)5-Oct ((C18)2L5-Oct), containing the octreotide bioactive peptide, is reported. Liposomes of
(C18)2-PKAG-Pt present a radius of 48 nm, whereas the mixed aggregates (C18)2-PKAG-Pt/(C18)2L5-Oct at 90/10M ratio give
larger liposomes with a radius of 84 nm. In both cases, the bilayer thickness is ~5.3 nm. Encapsulation of doxorubicin in mixed
liposomes is also obtained by using the pH gradient method. The obtained liposomes could represent a new target selective
cargo system for delivery of cisplatin based drugs and/or doxorubicin on cells overexpressing the sstr2 and sstr5 somatostatin
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(SP-4-2)-diamminedichloridoplatinum(II) (cisplatin) and many of
its analogs are currently used in the treatment of a large number
of solid tumors [1]. Despite the large use, the clinical treatments
based on platinum drugs ﬁnd three major problems: (i) serious
dose-limiting toxicities in particular nephrotoxicity, neurotoxicity
and ototoxicity; (ii) rapid inactivation of the drug as a result of
complexation to plasma and tissue proteins; and (iii) frequent
occurrence of platinum resistance [2–5]. One strategy to reduce
these side effects and save their therapeutic efﬁcacy lies in shield-
ing the drugs from the extracellular environment by means of a
lipid coating. The ability of liposomes to prevent organ speciﬁc
toxicities such as cardiotoxicity is well known [6]. These prepara-
tions exhibit an extended circulation time, increased anti-tumor
efﬁcacy and reduced toxicity compared with the free drug. More-
over, a liposomal formulation may overcome platinum resistance
by delivering a high dose of the administered drug at the tumor
site. Another advantage could lie in different mechanism of the
liposome to cross the cell membrane barrier.
Anyway, most of platinum drugs have low hydrophilicity and
at the same time a very low afﬁnity for the hydrophobic compart-
ment. For this reason, a very low drug-to-lipid ratio is found in
liposomal preparation [7–9]. Two strategies have been pursued
to increase the amount of platinum complexes in liposomes or
in other supramolecular aggregates. One approach is to synthe-
size lipophilic derivatives of cisplatin that can be efﬁciently en-
capsulated in large multilamellar liposomes [10]. The lipophilic
Pt complex NDDP is an example of such a complex, and its lipo-
somal formulation L-NDDP (aroplatin) has entered Phase II clinical
trials [10–13]. Furthermore, in order to improve the liposolubility
of NDDP, highly branched aliphatic carboxylate groups were
used, greatly increasing the molecular weight and makingJ. Pept. Sci. 2013; 19: 190–197passive diffusion through the cell membrane difﬁcult. Recently,
salicylate derivatives of platinum complexes have been efﬁciently
encapsulated showing greater antitumor activity and less toxicity
than carboplatin and oxaliplatin [14]. The second approach is
based on improving the loading methods by using highly water
soluble platinum complexes, for example, cis-diamminedinitrato-
platinum (II), as drug [15].
Several liposomal formulations of cisplatin have been already
proposed; anyway, some drawbacks have been found. ForCopyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.
OCTREOTIDE PLATINUM COMPLEXES AGGREGATESexample, negatively charged-lipid coated cisplatin nanocapsules
[16] fail in their clinical applications because of inefﬁcient encap-
sulation of the drug in lipid formulations limiting the bioavailabil-
ity and resulting in low drug uptake by the tumor [17–19], and
in the poor serum stability [20]. In liposome-coated cisplatin
SPI-077, high levels of platinum were detected at tumor sites
[7,21]. Despite a prolonged circulation time and enhanced tumor
uptake, this formulation showed little activity when evaluated
clinically [22]. In fact, they showed very low release kinetics of cis-
platin from the liposomes, resulting in poor therapeutic efﬁcacy
[18,23,24]. Another liposomal cisplatin formulation (Lipoplatin),
composed of DPPG, soy phosphatidyl choline, cholesterol and
mPEG-DSPE, is currently undergoing a number of Phase II and
Phase III clinical trials in combination with other cytotoxic agents,
demonstrating substantially reduced renal toxicity, peripheral
neuropathy, ototoxicity and myelotoxicity [25,26].
An improvement in the use of liposomes or other supramoleco-
lar aggregates as tools for drug delivery is based on the possibility
to decorate the external surface of the supramolecular carrier with
bioactive molecules to improve drug accumulation at tumor site.
For example, liposomes encapsulating As and Pt based drugs
were decorated by folate in order to target cells overexpressing
speciﬁc folate receptors [27].
In the last years, we developed new mixed aggregates modi-
ﬁed with a bioactive peptide on their external surface and able
to deliver contrast agents and/or drugs on tumor cells overex-
pressing the appropriate receptors for the chosen peptide [28].
These aggregates have been obtained by co-aggregation of
two monomers: the ﬁrst monomer containing a chelating agent
able to coordinate a radioactive or paramagnetic metal ion and
having a lipophilic moiety and the second monomer containing
a bioactive peptide linked to a similar lipophilic moiety [29,30],
or by using a single monomer containing in the same molecule
the bioactive peptide, the chelating agent and the lipophilic
moiety [31,32].
In this paper, we report on the synthesis, formulation and
physico-chemical characterization of new aggregates obtainedFigure 1. Schematic representation of the two amphiphilic monomers: (a) P
J. Pept. Sci. 2013; 19: 190–197 Copyright © 2013 European Peptide Society aby co-assembling an amphiphilic molecule containing a plati-
num complex with the second amphiphilic monomer containing
the octreotide bioactive peptide. The obtained liposomes could
represent a new target selective cargo system for delivery of
cisplatin based drugs on cells overexpressing the sstr2 and sstr5
somatostatin receptors. Moreover, the encapsulation of the
second drug (doxorubicin) is explored in order to develop target
selective delivery systems with two drugs.Results
Synthesis and Formulation
The schematic structure of the two monomers used to assemble
supramolecular aggregates is reported in Figure 1, both mono-
mers contain a hydrophobic moiety and a more hydrophilic
region. The hydrophobic region of the two monomers is based
on two aliphatic chains with 18 carbon atoms each. This hydro-
phobic moiety was chosen for its similarity to the components
of membrane phospholipidic bilayer, thus avoiding toxic and
haemolytic effects on the cells [33]. Moreover, the 18 carbon
atom chains provide sufﬁcient Van der Waals interactions to ob-
tain stable aggregates in water, also when diluted in the blood
for in vivo applications.
The monomer (C18H37)2NCO(CH2)2CO(AdOO)5-Oct ((C18)2L5-Oct)
was previously designed and already used by us, in order to vehicle
contrast agents to tumor cells overexpressing somatostatin recep-
tors [34]. It contains the cyclic peptide octreotide, a well known so-
matostatin analog, characterized by long in vivo stability and able
to bind with nanomolar afﬁnity, the somatostatin receptors sstr2
and sstr5. The bioactive peptide is spaced from the hydrophobic
moiety by ﬁve units of 8-amino-3,6-dioxaoctanoic acid (AdOO).
The ﬁve AdOO linkers, that constitute a PEG fragment, were chosen
both to increase the hydrophilicity of the head without changing
the monomer charge and to reduce aggregate clearance through
the reticulo-endothelial system [35].eg1500-Lys(Pt-aminoEtGly)-Lys(C18)2 ((C18)2-PKAG-Pt) and (b) (C18)2L5-Oct.
nd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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2The platinum containing amphiphilic monomer, Peg1500-Lys
(Pt-aminoEtGly)-Lys(C18)2, ( (C18)2-PKAG-Pt) was designed to fol-
low two requirements: (i) the platinum complex has to retain a
cytotoxic efﬁcacy also when it is bound to the entire monomer
and/or to the reconstituted liposome, and (ii) the hydrophilic
head has to contain a PEG chain to give hydrophilicity to the
head and to allow a long in vivo circulation time of the reconsti-
tuted liposomes. The monomer is based on a Lys–Lys moiety, in
which the ﬁrst Lys residue is derivatized with a Peg1500 moiety
on its a-amino function, and with N-2-aminoethylglycine chelat-
ing the PtCl2 fragment, on the epsilon amino function; the
second Lys residue is derivatized on the side-chain with the
hydrophobic moiety containing two 18 carbon atom chains. Both
monomers were synthesized in solid phase modifying the well
assessed procedure of SPPS with Fmoc strategy. The synthetic
pathway used to obtain (C18)2-PKAG-Pt is reported in Figure 2.
Following the synthetic procedure proposed by Reedjiak [36],
the platinum ion was added by reacting a stoichiometric amount
of K2PtCl4, dissolved in N-methyl-2-pyrrolidone (NMP)/water mix-
ture, with the free amino functions of N-2-aminoethylglycine
moiety present on the epsilon amino group of the Lys–Lys
fragment bound to the Rink amide resin. The monomer was
cleaved from the resin adding a TFA/H2O mixture. The TIS scaven-
ger, usually used in cleavage peptide procedure from resin, was
avoided. This molecule could favor the formation of platinum at
elementary state, through oxidative addition followed by a rapid
reductive elimination. The platinum monomer was puriﬁed by
crystallization steps by adding diethylether dropwise to TFA
cleavage solution. The product identity was conﬁrmed by ESI
MS and by 1H NMR spectroscopy. The presence of Pt(II) was
found 40% of that expected by ICP-MS measurements. Peaks
found in ESI MS spectrum correspond to the platinum complex
containing chloride ligands and platinum complexes in which
chloride atoms are substituted, during HPLC, with water mole-
cules because of the trans effect of the amino nitrogen atoms.
The ESI spectrum also shows the platinum complex withoutFigure 2. Scheme of synthesis, by solid phase methods, of (C18)2-PKAG-Pt
wileyonlinelibrary.com/journal/jpepsci Copyright © 2013 European Pechloride ligands and the full monomer lacking of the platinum
center.
Self assembling aggregates containing the platinum monomer
(C18)2-PKAG-Pt andmixed aggregates between platinummonomer
(C18)2-PKAG-Pt and peptide monomer (C18)2L5-Oct, at 90/10M
ratio, were prepared by well-assessed sonication and extrusion pro-
cedures in 0.1M phosphate buffer at pH 7.4 and physiological ionic
strength conditions (NaCl 0.9 wt%). Larger amount of peptide
monomer in the ﬁnal composition of mixed aggregates were
avoided in order to prevent inter-chain peptide interactions, and
to preserve the right peptide conformation for receptor binding.
Peptide concentration in mixed aggregates was determined by
UV spectroscopy. The exposure of the bioactive octreotide moiety
of the monomer containing peptides on aggregates surface was
evaluated by monitoring the ﬂuorescence emission produced by
the indole moiety of the tryptophan residue. Usually, this ﬂuoro-
phore shows an emission peak centered at 350nm in polar solvents,
whereas in hydrophobic solvents the maximum shifts to 330nm
[37]. A ﬂuorescence emission centered at 345nm was observed
conﬁrming the exposure of the most of the indole groups on the
hydrophilic surface of supramolecular aggregates. By considering
that the Trp-Lys fragment in a b-turn conformation is responsible
for octreotide and somatostatin binding to membrane receptors,
the found emission wavelength value allows to predict binding
properties for the entire aggregate. ICP-MSmeasurement conﬁrmed
the quantitative presence of platinum both in self-assembling and
in mixed supramolecular aggregates, thus indicating the complex
stability also during supramolecular aggregate preparation.
Dynamic Light Scattering and Small Angle Neutron
Scattering
In Figure 3, an example of the hydrodynamic radius distribution
function has been reported for the binary system (C18)2-PKAG-
Pt/water and for the ternary system (C18)2-PKAG-Pt/(C18)2L5-
Oct/water at 90/10M ratio among the two synthetic components.monomer.
ptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2013; 19: 190–197
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Figure 3. DLS measurements: (a) Hydrodynamic radius distribution func-
tions obtained at 25 C for (C18)2-PKAG-Pt and (C18)2-PKAG-Pt/(C18)2L5-Oct
(90/10M ratio) aqueous dispersions at pH 7.4; (b) Intensity correlation func-
tions at θ=90 for 1mM liposomal solution.
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Figure 4. Scattering cross-sections obtained at 25 C for (□) (C18)2-PKAG-Pt
and (○) (C18)2-PKAG-Pt/(C18)2L5-Oct (90/10M ratio) aqueous dispersions
at pH 7.4. Solid lines represent ﬁtting curves of the experimental data. To
allow for a better visualization, data have been multiplied for a scale factor,
as indicated in the plot.
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3In both cases, it is possible to observe that the distribution is
clearly mono-modal, i.e. there is a presence of a single mode.
Hydrodynamic radius Rh distribution function is strictly connected
to the diffusion coefﬁcient D distribution function through the
Stokes-Einstein
RH ¼ kBT6p0D
(1)
where kB is the Boltzmann constant, T is the absolute temperature
and  is the medium viscosity. Rigorously speaking, Eqn (1) holds
at inﬁnite dilution. However, because of high dilution, it can
be reasonably used to estimate the hydrodynamic radius of
the aggregates [38]. Extrapolation of diffusion data at zero angle,
i.e. zero q values, allows establishing the presence of aggregates
with diffusion coefﬁcients of (5.1 0.5)  108 cm2 s1 and
(2.9 0.3)  108 cm2 s1 for binary and ternary systems, respec-
tively. These values correspond to a mean radius of (48 4) nm
and (84 6) nm, for binary and ternary systems, respectively.
The found values fall in the typical range of vesicular or liposomal
aggregates and would be in agreement to the preparation
method of the aggregates.
In order to have information on the morphology of the aggre-
gates formed in the systems, SANS measurements have been car-
ried out and reported in Figure 4. Inspection of the ﬁgure allowsJ. Pept. Sci. 2013; 19: 190–197 Copyright © 2013 European Peptide Society aobserving the scattering cross-sections for both the systems scale
with a power law (dΣ/dΩ)/ q 2 typical of bi-dimensional struc-
tures such as sheets. Actually, the presence of large objects such
as unilamellar liposomes with radii of tens of nanometers does
not allow for a full characterization of these supramolecular struc-
tures, because their Guinier regime falls in the USANS domain
(q< 104 nm). Consequently, liposomes can be regarded as a col-
lection of randomly oriented planar sheets, whose cross-section
dependence on q is given by [39]:
dΣ
dΩ
¼ 2p rc  r0ð Þ2Sd2
1
q2
sin2 qd2
 
qd
2
 2 þ dΣdΩ
 
incoh
(2)
where d is the plane thickness, and S is the plain surface per unit
volume, and (dΣ/dΩ)incoh represents the incoherent contribution
to the total scattering cross-sections, mainly because of the pres-
ence of hydrogenated molecules in the systems. Fitting of Eqn (2)
to the experimental data, also reported in Figure 4, allows obtain-
ing an estimation of the lateral thickness of the liposome double
layer, which results to be (5.3 0.2) nm for ternary and binary
systems.
Doxorubicin Loading
Doxorubicin was loaded in mixed liposomes by using the pH gra-
dient method [40]. Liposomes were prepared at pH 4.0, and then
the pH outside the liposomes was brought to 7.4 by adding
NaOH dropwise. Doxorubicin loading content (DLC) was calcu-
lated by UV–vis measurements for subtraction of the amount of
free doxorubicin, eluted by gel ﬁltration, from the total amount
of initial doxorubicin. Several loading assays were carried out to
optimize the DLC. Four different percentage of drug (wt)/lipid
(wt) from 0.025 to 0.1 were used. An encapsulation >95% was
observed at 0.025 (drug (wt)/lipid (wt)). This ratio is lower with re-
spect to the other liposome such as commercially available lipo-
somes (Myocet and Doxil). However, because of higher molecular
weight of monomers used in this formulation respect to wide-
spread phospholipids, the molar ratio is comparable with that
used for Myocet and Doxil. In the ﬁnal formulation, the amount
of platinum complex was 2105mol, whereas the amount of
doxorubicin is tenfold lower (2106mol). DLS measurementsnd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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4indicate that liposome structure and size do not change after
doxorubicin loading (data not shown).Discussion
In last year, liposomal carriers for drug delivery have been easily
obtained by using natural or synthetic phospholipids; these
molecules are commercially available, also in GMP grade, and
guarantee high in vivo stability and low toxicity of the supramo-
lecular aggregates they form in water solution. Generally, the size
of the liposomes is appropriate for in vivo use and is not affected
by drug encapsulation process. As a consequence, about one-
tenth of liposomal drugs have been introduced in the market
and others are currently in development or already used in clini-
cal studies.
More recently, liposomes have also been obtained employing
synthetic amphiphilic monomers opportunely designed to intro-
duce special functions on the ﬁnal aggregate such as targeting
molecules or metal complexes acting as contrast agents in MRI
or in nuclear medicine [28–34].
Now, we have obtained new supramolecular aggregates by
self-assembling, in water solution, a synthetic amphiphilic mono-
mer containing a platinum complex, a long PEG chain, and a
hydrophobic moiety with two C18 alkyl chains. The liposome
structure has been deeply characterized by dynamic light scatter-
ing and SANS measurements, and it is schematized in Figure 5.
The PEG moiety in the monomer structure is essential to give
hydrophilicity to the monomer head allowing liposome forma-
tion: a similar monomer lacking of the PEG chain on the lysine
a-amino function results completely insoluble in water solution
and does not aggregate in supramolecular structures (data not
shown). Moreover, the advantage of pegylated liposomes respect
to non-pegylated aggregates has been well assessed for drug de-
livery purpose: in fact, liposome coating with PEG moieties allows
a longer in vivo circulating time and confers stealth properties to
the aggregates [41]. ICP measurements obtained on the single
monomer (C18)2-PKAG-Pt indicate that only 40% of the chelating
agent N-2-aminoethylglycine in the single monomers complex
the platinum(II) ion; anyway, the platinum(II) ion remains stableFigure 5. Schematic representation and physic-chemical parameters of (C18
Pt/(C18)2L5-Oct/doxorubicin liposomes.
wileyonlinelibrary.com/journal/jpepsci Copyright © 2013 European Pecomplexed to the two amino functions, as conﬁrmed by compar-
ing ICP data, on the single amphiphilic monomer and on the ag-
gregate formulations. The other two ligands of the platinum(II)
center, in its square-planar structure, are chloride ions or water
molecules according to the solution composition, as in the case
of cisplatin [Cl2Pt(NH3)2], in which the chloride ions are substi-
tuted by water molecules in the cell environment characterized
by low chloride concentration. The biological activity of plati-
num(II) ions complexed by N-2-aminoethyl-glycine bound to
peptide sequences in monomeric peptide derivatives has been
already studied by Reedijk [36] and by Mancini [42]. They found
a cytotoxic activity lower than cisplatin; in the aggregate formu-
lation based on Peg1500-Lys(Pt-aminoEtGly)-Lys(C18)2, the pres-
ence of a large amount of platinum complexes, even if with
reduced cytotoxic activity of each platinum center, should give
a potential high cytotoxic efﬁcacy to the full liposome.
Figure 5 also reported a schematic structure, and the geomet-
rical parameters of mixed liposomes in which 10% of the amphi-
philic monomers are constituted by the (C18)2L5-Oct peptide
containing monomer. An increase of about 70% of the hydrody-
namic radius of the mixed aggregates respect to self-assembling
liposomes is observed. This increase could be probably because
of the presence of the octreotide peptide on the liposome exter-
nal surface. The exposition of the octreotide peptide, conﬁrmed
by ﬂuoresce data, could assure targeting properties of the plati-
num containing aggregate to cancer cells overexpressing the
sstr2 and/or sstr5 somatostatin receptors. Moreover, it seems rea-
sonable to expect that the platinum containing liposomes could
be efﬁciently modulated by inserting in the ﬁnal composition
other (C18)2L5-peptide amphiphilic monomers containing bioac-
tive peptides to target other biologically relevant receptors for
selective drug delivery.
Finally, we have investigated the possibility to obtain target se-
lective multi-drug delivery systems by coupling the platinum
based drug and the well known cytotoxic doxorubicin in the
same liposomal cargo. Loading data conﬁrm that the proposed
procedure allows obtaining doxorubicin encapsulation in the in-
ner liposome compartment without structural modiﬁcation of
the cargo system, as conﬁrmed by DLS data (Figure 5). The com-
bined use of doxorubicin and platinum based drugs is a very)2-PKAG-Pt; (C18)2-PKAG-Pt/(C18)2L5-Oct (90/10M ratio); and (C18)2-PKAG-
ptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2013; 19: 190–197
OCTREOTIDE PLATINUM COMPLEXES AGGREGATESimportant approach in several tumor therapeutic purposes. The
results obtained in A Multi-National, Randomized, Phase III, GCIG
Intergroup Study Comparing Pegylated Liposomal Doxorubicin
(CAELYXW) and Carboplatin vs. Paclitaxel and Carboplatin
(CAPYPSO trials) demonstrate a superior therapeutic index re-
spect to carboplatinum in relapsed/recurrent ovarian cancer [43].1
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5Materials and Methods
General Experimental Procedures
Protected Na-Fmoc-amino acid derivatives, coupling reagents
and Rink amide MBHA resin were purchased from Calbiochem–
Novabiochem (Laufelﬁngen, Switzerland). Fmoc-AdOO-OH was
purchased from Neosystem (Strasbourg, France). Fmoc-Peg1500-OH
was purchased by Iris Biotech (Marktredwitz, Germany).
N,N-dioctadecylsuccinamic acid was prepared according to the ex-
perimental procedure reported in literature [44]; N-Fmoc[N0-Fmoc
2-aminoethyl]Gly-OH was obtained by Fmoc protection of the
commercially available [N0-Fmoc-2-aminoethyl]Gly-OH (Bachem,
Switzerland). K2PtCl4 and all other chemicals were commercially avail-
able by Sigma-Aldrich (St. Louis MO USA), Fluka (Buchs, Switzerland)
or LabScan (Stillorgan, Dublin, Ireland) and were used as received
unless otherwise stated. All solutions were prepared by weight
using double distilled water. Samples to be measured by SANS
techniques were prepared using heavy water (Sigma-Aldrich,
purity> 99.8%). The pH of all solutions was kept constant at 7.4.
Synthesis of peptide conjugate was carried out as previously
describe in solid phase under standard conditions using Fmoc
strategy [45]. Experimental conditions for puriﬁcation and identi-
ﬁcation data have been reported elsewhere [34].
Synthesis of Peg1500-Lys(Pt-aminoEtGly)-Lys(C18)2 ((C18)2-
PKAG-Pt)
Synthesis of platinum containing amphiphilic monomer was car-
ried out in solid phase under standard conditions using Fmoc/tBu
strategy. Rink amide MBHA resin (0.55mmol g1, 0.1mmol scale,
0.180 g) was used as polymeric support. The Na-protecting group
on the resin was removed by DMF/piperidine (70/30) mixture.
Dde-Lys(Fmoc)-OH residue (0.186 g, 0.2mmol) was activated by
1 equivalent of HBTU and HOBt, and 2 equivalents of DIPEA in
DMF and coupled on the resin stirring the slurry suspension for
1 h. The coupling was repeated twice. Then, the Ne-Fmoc protect-
ing group of the lysine residue was removed and 0.124 g
(0.2mmol) of N,N-dioctadecylsuccinamic acid was condensed
twice for 1 h in DMF/DCM (1/1) mixture. The lipophilic moiety
was activated in situ by the standard HOBt/HBTU/DIPEA proce-
dure. The coupling was monitored by the qualitative Kaiser test.
After the Dde protecting group removal by a solution of 2%
hydrazine solution in DMF, a Dde-Lys(Fmoc)-OH residue was
coupled to H-Lys(Fmoc). Then, the Ne-Fmoc protecting group
of the lysine residue was removed, and N-Fmoc[N0-Fmoc-2-
aminoethyl]Gly-OH was linked to the e-amino group. The
coupling was performed in DMF using 2 equivalents of N-Fmoc
[N0-Fmoc-2-aminoethyl]Gly-OH (0.117 g) activated with HBTU
and HOBt. After the assembly was complete, the Fmoc groups
were removed and K2PtCl4 0.05M in NMP/H2O (9 : 1 v/v, 10ml)
was added and leaved under stirring for 24 h. The resin was ﬁl-
tered and washed with H2O and NMP. Upon cleavage of the
Dde protecting group, 308mg Fmoc-Peg1500-OH (2 equivalents)
was added and activated by HOBt and HBTU in DMF. AfterJ. Pept. Sci. 2013; 19: 190–197 Copyright © 2013 European Peptide Society a1 h, the resin was washed with DMF, DCM and treated with TFA/
H2O (95 : 5 v/v, 2.5ml) for 1.5 h. After ﬁltration, the resin was
washed with TFA, and the combined TFA ﬁltrates was precipitated
with Et2O in a cold bath at 0 C. The product was recollected in
good yield and used without further puriﬁcation.
ESI MS (positive ions) peaks: [M+ 3H]3+/3 = 843 a.m.u.. (calcu-
lated 2529 a.m.u.), [M 2Cl]2+/2 = 1230 a.m.u. (calculated 2460 a.
m.u.), [M 2Cl + 2H2O]2+/2 = 1248 a.m.u. (calculated 2496 a.m.u.),
[M Pt 2Cl + 2H]2+/2 = 1132 a.m.u. (calculated 2260 a.m.u.).
1H NMR (CD3OD) d: 3.78 (m, 2H, a Lys). 3.2, 3.31 (m, 4H, e Lys),
3.00 (s, 27H, OCH3), 2.75 (m, 2H, CH2N), 2.53 (m, 2H, CH2N), 2.49
(m, 2H, CH2NH2), 2.39 (m, 4H, COCH2), 1.62 (m, 2H, d Lys), 1.53
(m, 4H, g Lys), 1.44 (m, 4H, d Lys), 1.34 (m, 4H, b LH2 Lys), 1.30
(m, 64H,) 0.90 (t, 6H)
ICP measurements: ICP (calc): 1555 ppb (3900 ppb). Yield: 40%.
Liposome Preparation
Self assembling and mixed aggregates at 90/10M ratio were pre-
pared by dissolving the components in a small volume (2.0ml) of
50/50methanol/chloroformmixture. After removing solvent under
N2 ﬂow, the lipidic ﬁlm was hydrated in 0.1M phosphate buffer at
pH 7.4 and physiological ionic strength conditions (NaCl 0.9 wt%),
sonicated for 30min and extruded 10 times through a 0.1mm car-
bonate membrane. Water volume used allows obtaining 2103M
liposome solutions. Peptide concentration in mixed aggregates
was determined by absorbance on a UV–vis Jasco V-5505 spectro-
photometer (Easton, MD, USA) equipped with a Jasco ETC-505T
Peltier temperature controller with a 1-cm quartz cuvette using a
molar absorptivity (e280) of 5630M
1 cm1 for octreotide, because
of the contribution of tryptophan residue present in the primary
octreotide structure.
Fluorescence Measurements
Emission spectrum was recorded using a Jasco Model FP-750
spectroﬂuorometer (Jasco Easton, MD, USA) equipped with a
Peltier temperature controller in 1.0 cm path length quartz cell at
25 C. Equal excitation and emission bandwidths (5nm) were used
throughout experiments, with a recording speed of 125 nmmin1
and automatic selection of the time constant. The tryptophan emis-
sion spectrum in 290–450nm range was obtained exciting at
280 nm liposome solution.
DLS Measurements
DLS investigations were performed at (25.00 0.05) C with a
home assembled instrument composed by a Photocor compact
goniometer, a 50mW light source operating at 532.5 nm and a
PMT correlator purchased from Correlator.com. Temperature
was kept constant through the use of a thermostat bath.
In all the experiments, the intensity autocorrelation function
has been measured and, through a variation of CONTIN algo-
rithm, the diffusion coefﬁcient distribution function has been
obtained at various angles, from 30 to 90. Finally, the z-average
of the diffusion coefﬁcient D has been obtained from extrapola-
tion of diffusion data [46]:
D ¼ lim
q!0
D qð Þ (3)
where q= 4pn0/l sin(θ/2) is the modulus of the scattering vector,
n0 is the refractive index of the solution, l is the incident wave-
length and θ represents the scattering angle.nd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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SANSmeasurements have been performed at 25 C with the KWS2
instrument located at the Heinz Maier-Leibnitz neutron source
of the Jülich Centre for Neutron Science (Garching, Germany).
Neutrons with an average wavelength of 0.7 and 1,9 nm and
a wavelength spread Δl/l ≤ 0.2 were used. A two-dimensional
128 128 array scintillation detector at two different collimation
(C)/sample-to-detector(D) distances (C8D8 and C8D2, with all the
lengths expressed in m) measured neutrons scattered from the
samples. These conﬁgurations allowed collecting data in a range
of the scattering vector modulus q=4p/l sin(θ/2) located between
0.0002 and 0.025 nm–1. The obtained raw data were then cor-
rected for background and empty cell scattering. Detector efﬁ-
ciency corrections, radial average and transformation to absolute
scattering cross-sections were made with a secondary plexiglas
standard [47,48].Doxorubicin Loading
(C18)2-PKAG-Pt/(C18)2-L5Oct/Doxo liposomal formulation was
prepared by remote loading using the pH gradient method.
Brieﬂy, 2103M liposomal solution was prepared as reported
earlier at pH 4.0 by using 0.1M citrate-phosphate buffer. Then,
pH was adjusted from 4.0 to pH 7.4 adding dropwise a stock so-
lution of 1.0M NaOH, and 100ml of 2.1  103M doxorubicin solu-
tion was added to 1.0ml of liposomal solution. This suspension
was stirred for 1 h at 60 C. Doxorubicin concentration, in all
experiments, was determined by spectroscopic measurements
(UV–vis) using calibration curves obtained by measuring absor-
bance at 480 nm. Subsequently, unloaded doxorubicin was re-
moved by using a Sephadex G50 (Amersham Pharmacia Biotech
Inc (Piscataway, NJ USA)) column pre-equilibrated 0.1M phos-
phate buffer at pH 7.4. The DLC (deﬁned as the weight ratio of
the encapsulated doxorubicin vs the amount of the amphiphilic
moieties) was quantiﬁed for subtraction of the amount of doxo-
rubicin removed from the total amount of doxorubicin loaded.Acknowledgements
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